China's Leading Health Screening Company Earns Nearly RMB 4 Billion with AI Amid 2026 'Model-Data Resonance' Initiative

1. China's Ministry of Industry and Information Technology and National Data Administration Launch the 2026 "Model-Data Resonance" Initiative

Recently, the Ministry of Industry and Information Technology and the National Data Administration jointly issued a notice to officially launch the 2026 "Model-Data Resonance" initiative. Targeting 20 key industries in the manufacturing sector, the initiative will identify a group of key cities to explore output pathways for core technology achievements such as scenarios, models, intelligent agents, datasets, and case studies, thereby promoting high-level artificial intelligence empowerment for new industrialization. Through this joint effort by the two departments to initiate the 2026 "Model-Data Resonance" action, specific operational paths for advancing “AI + Manufacturing” have been further detailed for all regions and departments. By setting key tasks, the initiative focuses on promoting the deep integration of models and data, forming a virtuous flywheel of "industry models empowering application practices, application practices generating scenario data, and scenario data optimizing industry models." (The Paper)

2. The proposed results of the national joint procurement of cardiac pacemakers in 27 provinces of China have been announced.

Recently, the Zhejiang Provincial Medical Insurance Bureau announced the provisional winning results of the inter-provincial alliance procurement for medical consumables such as pacemakers, reaching the scale of a "small national procurement," covering 27 provinces and the Xinjiang Production and Construction Corps, with a procurement cycle of three years. The total annual demand is 84,800 units for conventional pacemakers, 5,639 units for leadless pacemakers, and 171,400 electrode leads. Major companies including Medtronic, Abbott, Biotronik, and Boston Scientific, which rank among the top five in hospital demand, have all been provisionally selected. These four multinational enterprises previously accounted for over 80% of the demand, with a share of more than 90% for high-end products. Prior to this procurement, the prices of pacemakers remained high, ranging from tens of thousands to hundreds of thousands of yuan per unit. After the procurement, prices generally fell within the range of ten thousand to one hundred thousand yuan. The specific price reduction figures for this procurement have not been announced yet, but the expected decrease is considered to be more significant compared to previous winning bids. (MedTrend)

3. Jiangsu Spede Technology Builds AI-Driven, Digital and Intelligent Medical Record Integration Platform

Recently, the 30th China Hospital Information Network Conference and Medical Information Technology and Products Exhibition (CHIMA 2026) successfully concluded in Zhuhai. Jiangsu Spede Technology was invited to participate, showcasing its core achievements in paperless medical record management, AI-powered intelligent quality control, trusted data interaction, and public convenience services under the central theme of "AI-Driven Integrated Solution for Digital and Intelligent Medical Records." With solid technical expertise, product designs closely aligned with clinical needs, and comprehensive service capabilities, Spede Technology became one of the highlights of the exhibition. At the event, Spede Technology presented its four core product systems centered around the "AI-Driven Integrated Solution for Digital and Intelligent Medical Records." These systems worked collaboratively and provided layered support, forming a fully digitalized service loop covering the entire paperless medical records process, precisely aligning with national policies on healthcare informatization and innovation construction. (CHIMA)

4. China's Leading Health Check Company Earns Nearly 400 Million with AI

In recent years, although Meinian Health's operating revenue, gross profit margin, number of stores, number of physical examinations, and average revenue per customer have all declined, the application of AI technology has generated 370 million yuan in revenue, representing a year-on-year increase of 71.9%. This achievement is attributed to the company’s vast accumulation of imaging and health data. AI not only offset the pressure from the decline in core business revenue but also promoted the commercialization of "AI + Health Management" products. Additionally, Meinian Health has shifted its focus to full-chain health management, driving dual growth through group and individual check-ups, while upgrading its digital marketing and service models to enhance long-term customer value. The application of AI has permeated every aspect, including marketing, medical quality, customer service, and internal management, becoming a key operational lever. (Zhen Suo Jie)

5. 16 Core Projects Focus on Incubating Industrial Chain Accelerates Operation

Recently, the Medical-Engineering Cross-Innovation Research Institute of Shenyang University of Technology was officially established. Sixteen core projects have been centrally incubated, and ten medium- to long-term projects have been included in the reserve pool, establishing a full-chain innovation ecosystem covering "basic research – applied R&D – pilot conversion – industrial incubation," with a focus on key areas such as high-end medical devices. As an important carrier for Shenyang's development of new productive forces, the Shenyang International Life Science and Health City focuses on key areas like biomedicine, aiming to create a new highland for the life health industry in Northeast Asia. The Innovation and Research Institute of Shenyang University of Technology leverages the platform and industrial cluster advantages of the Life Science and Health City and is confident in achieving outstanding results in the transformation of scientific achievements. Its establishment also represents a concrete action to implement Liaoning Province’s “15th Five-Year Plan.” (Sina)

6. 3Shape Receives FDA 510(k) Clearance for 3Shape Dx Software

Recently, 3Shape announced that the U.S. Food and Drug Administration (FDA) has granted FDA clearance for its Dx software following a completed review. The 510(k) premarket notification allows the Dx (R1) software to be marketed in the United States for use by qualified dental professionals in dental clinics to help diagnose critical oral health conditions and assess changes in adult patients' teeth and gums. The FDA clearance applies to two versions of 3Shape's Dx software: Dx Plus and Dx Standard. The software is only compatible with the 3Shape TRIOS 6 scanner. Dx Plus is an artificial intelligence software that assists in detecting key oral health conditions, including surface and interproximal caries, plaque, tooth wear, and gum recession. The software can help dentists engage patients by manually tracking and quantifying changes in their teeth. (CISION)

7. What is the medical device public service platform?

The Medical Device Public Service Platform is jointly developed by the Oshine Group with local governments, parks, medical institutions, and research universities. It focuses on incubating, transforming, and investing in cutting-edge and innovative global medical device technology projects. By establishing scientific research and transfer mechanisms aligned with international standards and implementing an open and shared operational model, it attracts top-level scientific researchers, doctors, and innovators from around the world to join. The platform provides comprehensive industrial technical services that integrate R&D transformation, incubation, and investment, nurturing major innovative achievements with significant application value in medical devices. This initiative strongly supports the development of the medical device industry and technological innovation. (Compiled by Oshine)

8. Layer浪 Bio Completes Financing of Tens of Millions of Yuan

Recently, Beijing Cenglang Biotechnology Co., Ltd., a well-known enterprise in China's flow cytometry field, announced the completion of a multi-million-yuan financing round. This round was exclusively invested by Sunshine Ronghui Capital, with StarBridge Capital serving as the exclusive financial advisor. This marks the second time Cenglang Biotechnology has gained capital market favor following its financing in March 2024, demonstrating the industry’s widespread recognition of the innovation capabilities and commercial prospects of domestically produced high-end flow cytometry technology. Since its establishment in 2020, Cenglang Biotechnology has been committed to overcoming the "bottleneck" technologies in flow cytometers. Leveraging deep technical expertise, the company has continuously launched domestically produced products such as the 2-laser 8-color MateCyte, the 3-laser 14-color LongCyte, the FongCyte, and the 4-laser FongCyte S, achieving key breakthroughs and becoming a representative company in China’s flow cytometry sector. (VcBeat)